DE1767891C3 - Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat - Google Patents
Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem TetracyclinderivatInfo
- Publication number
- DE1767891C3 DE1767891C3 DE1767891A DE1767891A DE1767891C3 DE 1767891 C3 DE1767891 C3 DE 1767891C3 DE 1767891 A DE1767891 A DE 1767891A DE 1767891 A DE1767891 A DE 1767891A DE 1767891 C3 DE1767891 C3 DE 1767891C3
- Authority
- DE
- Germany
- Prior art keywords
- doxycycline
- solution
- parenteral
- water
- peroral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004098 Tetracycline Substances 0.000 title claims description 16
- 235000019364 tetracycline Nutrition 0.000 title claims description 16
- 150000003522 tetracyclines Chemical class 0.000 title claims description 16
- 229960002180 tetracycline Drugs 0.000 title claims description 13
- 229930101283 tetracycline Natural products 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 49
- 229960003722 doxycycline Drugs 0.000 claims description 47
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 28
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 150000002681 magnesium compounds Chemical class 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000395 magnesium oxide Substances 0.000 description 11
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 11
- 229960000869 magnesium oxide Drugs 0.000 description 11
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 11
- 239000004100 Oxytetracycline Substances 0.000 description 9
- 229960000625 oxytetracycline Drugs 0.000 description 9
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 9
- 235000019366 oxytetracycline Nutrition 0.000 description 9
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 5
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 5
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960002337 magnesium chloride Drugs 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- -1 nicotinic acid amide Chemical class 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 229940040944 tetracyclines Drugs 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000001755 magnesium gluconate Substances 0.000 description 2
- 229960003035 magnesium gluconate Drugs 0.000 description 2
- 235000015778 magnesium gluconate Nutrition 0.000 description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- LJVDOBHBFMLPMI-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-bromo-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Br)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O LJVDOBHBFMLPMI-XRNKAMNCSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QJQZEJFUIOWFMS-UHFFFAOYSA-N formaldehyde;sulfanediol Chemical class O=C.OSO QJQZEJFUIOWFMS-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1767891A DE1767891C3 (de) | 1968-06-28 | 1968-06-28 | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
| GB1228629D GB1228629A (OSRAM) | 1968-06-28 | 1968-10-22 | |
| IL32350A IL32350A (en) | 1968-06-28 | 1969-06-05 | Doxycycline solution for parenteral,oral and topical uses |
| NL6908919A NL6908919A (OSRAM) | 1968-06-28 | 1969-06-11 | |
| BE734723D BE734723A (OSRAM) | 1968-06-28 | 1969-06-18 | |
| FI1809/69A FI44395B (OSRAM) | 1968-06-28 | 1969-06-18 | |
| NO2515/69A NO130624C (OSRAM) | 1968-06-28 | 1969-06-18 | |
| ES368496A ES368496A1 (es) | 1968-06-28 | 1969-06-18 | Procedimiento para la preparacion de soluciones acuosas de doxiciclina, para uso parenteral, oral y local. |
| CH933769A CH522407A (fr) | 1968-06-28 | 1969-06-18 | Procédé pour la préparation de solutions pour usages parentéral, oral et topique de la doxycycline |
| AT586269A AT291441B (de) | 1968-06-28 | 1969-06-19 | Verfahren zur Herstellung von wässerigen Lösungen von α-6-Desoxy-5-hydroxytetracyclin |
| DK329869AA DK127168B (da) | 1968-06-28 | 1969-06-19 | Fremgangsmåde til fremstilling af klare, stabile vandige opløsninger af doxycyclin, som er egnede til parenteral, oral og topisk brug. |
| MX100333U MX3351E (es) | 1968-06-28 | 1969-06-19 | Procedimiento mejorado para la preparacion de una solucion acuosa de doxiciclina |
| SE6908788A SE373036B (OSRAM) | 1968-06-28 | 1969-06-19 | |
| FR696920595A FR2011764B1 (OSRAM) | 1968-06-28 | 1969-06-19 | |
| IE845/69A IE33167B1 (en) | 1968-06-28 | 1969-06-19 | Doxycycline solution for parenteral,oral and topical uses |
| BR209929/69A BR6909929D0 (pt) | 1968-06-28 | 1969-06-19 | Solucao de doxiciclina para usos parenteral oral e topico |
| US836591A US3674859A (en) | 1968-06-28 | 1969-06-25 | Aqueous doxycycline compositions |
| MY15/73A MY7300015A (en) | 1968-06-28 | 1973-12-30 | Doxycycline solution for parenteral,oral and topical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1767891A DE1767891C3 (de) | 1968-06-28 | 1968-06-28 | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1767891A1 DE1767891A1 (de) | 1971-07-08 |
| DE1767891B2 DE1767891B2 (de) | 1980-02-21 |
| DE1767891C3 true DE1767891C3 (de) | 1980-10-30 |
Family
ID=5699525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1767891A Expired DE1767891C3 (de) | 1968-06-28 | 1968-06-28 | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US3674859A (OSRAM) |
| AT (1) | AT291441B (OSRAM) |
| BE (1) | BE734723A (OSRAM) |
| BR (1) | BR6909929D0 (OSRAM) |
| CH (1) | CH522407A (OSRAM) |
| DE (1) | DE1767891C3 (OSRAM) |
| DK (1) | DK127168B (OSRAM) |
| ES (1) | ES368496A1 (OSRAM) |
| FI (1) | FI44395B (OSRAM) |
| FR (1) | FR2011764B1 (OSRAM) |
| GB (1) | GB1228629A (OSRAM) |
| IE (1) | IE33167B1 (OSRAM) |
| IL (1) | IL32350A (OSRAM) |
| MX (1) | MX3351E (OSRAM) |
| MY (1) | MY7300015A (OSRAM) |
| NL (1) | NL6908919A (OSRAM) |
| NO (1) | NO130624C (OSRAM) |
| SE (1) | SE373036B (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957980A (en) * | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| GB1350196A (en) * | 1972-10-26 | 1974-04-18 | Pfizer | Doxycyline parenteral composition |
| US3928592A (en) * | 1974-02-22 | 1975-12-23 | Lilly Co Eli | Antibiotic pharmaceutical compositions |
| GB1538903A (en) * | 1975-04-11 | 1979-01-24 | Nelson Res & Dev | Carrier for a topically applied physiologically active agent or cosmetic agent |
| US4018889A (en) * | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| GB1592053A (en) * | 1976-12-16 | 1981-07-01 | Norbrook Lab Ltd | Oxytetracycline compositions |
| US4213963A (en) * | 1978-12-14 | 1980-07-22 | Janssen Pharmaceutica N.V. | Fluspirilene-containing compositions |
| IE74244B1 (en) * | 1985-10-01 | 1997-07-16 | Bimeda Res Dev Ltd | A process for preparing an antibiotic composition |
| US6756365B2 (en) * | 1991-11-06 | 2004-06-29 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| US8106225B2 (en) * | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| US6500812B2 (en) | 1999-09-14 | 2002-12-31 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| US6849615B2 (en) | 1999-09-14 | 2005-02-01 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| EP1666453A1 (en) | 1999-09-14 | 2006-06-07 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| CA2397863A1 (en) * | 2000-01-24 | 2001-07-26 | Trustees Of Tufts College | Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| ES2288945T3 (es) * | 2000-03-31 | 2008-02-01 | Trustees Of Tufts College | Compuestos de tetraciclina 7 y 9-carbamato, urea, tiourea, tiocarbamato y heteroaril-amino sustituidos. |
| DE60102815D1 (de) * | 2000-05-15 | 2004-05-19 | Paratek Pharm Innc | 7-substituierte kondensierte ring-tetrazyclin- verbindungen |
| US20040224927A1 (en) * | 2000-06-16 | 2004-11-11 | Trustees Of Tufts College | 7-N-substituted phenyl tetracycline compounds |
| US20020132798A1 (en) * | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| AU2001268475A1 (en) * | 2000-06-16 | 2002-01-02 | Trustees Of Tufts College | 7-phenyl-substituted tetracycline compounds |
| US7094806B2 (en) | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| DE60144375D1 (de) | 2000-07-07 | 2011-05-19 | Trustees Of Tufts College Medford | 7-, 8- und 9-substitutierte tetracyclinverbindungen |
| SI1301467T1 (sl) | 2000-07-07 | 2007-02-28 | Tufts College | 9-substituirane minociklinske spojine |
| EP1301465A2 (en) | 2000-07-07 | 2003-04-16 | Trustees Of Tufts College | 13-substituted methacycline compounds |
| US20050143353A1 (en) * | 2000-07-07 | 2005-06-30 | Paratek Pharmaceuticals, Inc. | 13-Substituted methacycline compounds |
| EA006170B1 (ru) * | 2000-07-07 | 2005-10-27 | Трастис Оф Тафтс Коллидж | Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния субъекта |
| US6683068B2 (en) * | 2001-03-13 | 2004-01-27 | Paratek Pharmaceuticals, Inc. | 7, 9-substituted tetracycline compounds |
| CA2440757A1 (en) | 2001-03-14 | 2002-09-19 | Michael Draper | Substituted tetracycline compounds as synergistic antifungal agents |
| US6841546B2 (en) | 2001-03-14 | 2005-01-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds as antifungal agents |
| DE60235083D1 (de) | 2001-04-24 | 2010-03-04 | Paratek Pharm Innc | Substituierte tetracyclin-verbindungen zur behandlung von malaria |
| US8088820B2 (en) * | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| JP2005514410A (ja) | 2002-01-08 | 2005-05-19 | パラテック ファーマシューティカルズ インコーポレイテッド | ４−デジメチルアミノテトラサイクリン化合物 |
| JP2005516032A (ja) | 2002-01-23 | 2005-06-02 | デンツプライ インターナショナル インコーポレーテッド | 洗浄液とその使用法 |
| JP2005526754A (ja) | 2002-03-08 | 2005-09-08 | パラテック ファーマシューティカルズ インコーポレイテッド | アミノメチル置換されたテトラサイクリン化合物 |
| JP2005520846A (ja) | 2002-03-21 | 2005-07-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 置換されたテトラサイクリン化合物。 |
| EP1534300A4 (en) | 2002-07-12 | 2008-04-23 | Paratek Pharm Innc | TETRACYCLINE COMPOUNDS SUBSTITUTED IN 3, 10, AND 12A |
| AU2003287218C1 (en) | 2002-10-24 | 2010-07-15 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| CA2531732C (en) | 2003-07-09 | 2012-04-10 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| US20060287283A1 (en) * | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| EP2319828A3 (en) | 2003-07-09 | 2011-07-06 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| AU2004261143B2 (en) * | 2003-07-25 | 2009-11-05 | Allergan Pharmaceuticals International Limited | A doxycycline metal complex in a solid dosage form |
| EP2332904A3 (en) | 2004-01-15 | 2012-04-11 | Paratek Pharmaceuticals, Inc. | Derivatives of tetracycline compounds |
| TWI261038B (en) * | 2004-08-11 | 2006-09-01 | Bo-Cheng Chen | Bicycle gear-shifting handgrip |
| EP2287148A3 (en) | 2004-10-25 | 2011-10-26 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP1805134B1 (en) * | 2004-10-25 | 2012-06-20 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
| NZ556582A (en) * | 2005-01-21 | 2010-12-24 | Warner Chilcott Co Llc | A tetracycline metal complex in a solid dosage form |
| JP2008530023A (ja) * | 2005-02-04 | 2008-08-07 | パラテック ファーマシューティカルズ インコーポレイテッド | テトラサイクリン化合物の１１ａ，１２−誘導体 |
| WO2007014154A2 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| EP1991236A2 (en) | 2006-01-24 | 2008-11-19 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
| JP4205731B2 (ja) * | 2006-04-05 | 2009-01-07 | 株式会社日本触媒 | ポリビニルピロリドン粉体組成物およびその製造方法 |
| WO2007120913A2 (en) * | 2006-04-17 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Isolation of tetracycline derivatives |
| CN101479235B (zh) * | 2006-04-24 | 2013-09-18 | 特瓦制药工业有限公司 | 替加环素晶形及其制备方法 |
| US8198470B2 (en) * | 2006-04-24 | 2012-06-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form II of tigecycline and processes for preparation thereof |
| AU2007249695A1 (en) * | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| WO2008045507A2 (en) | 2006-10-11 | 2008-04-17 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of bacillus anthracis infections |
| PT2109602E (pt) | 2006-12-21 | 2014-05-23 | Paratek Pharm Innc | Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias |
| SI2120963T1 (sl) | 2006-12-21 | 2019-02-28 | Paratek Pharmaceuticals, Inc. | Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj |
| JP5121470B2 (ja) * | 2007-01-26 | 2013-01-16 | 株式会社日本触媒 | ポリビニルピロリドン粉体組成物 |
| US7935687B2 (en) * | 2007-04-12 | 2011-05-03 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| CA2688662A1 (en) | 2007-04-27 | 2008-11-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| ATE555079T1 (de) | 2007-07-06 | 2012-05-15 | Paratek Pharm Innc | Verfahren zur synthese von 9-substituiertem minocyclin |
| CN102015602A (zh) | 2008-03-05 | 2011-04-13 | 帕拉特克药品公司 | 米诺环素化合物及其使用方法 |
| PT2271348T (pt) | 2008-03-28 | 2018-04-16 | Paratek Pharm Innc | Formulação de comprimido oral de composto de tetraciclina |
| US20100022483A1 (en) * | 2008-04-14 | 2010-01-28 | Paratek Pharmaceuticals, Inc. | Substituted Tetracycline Compounds |
| TW202021946A (zh) | 2008-05-19 | 2020-06-16 | 美商派洛泰克藥物股份有限公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| AP2011005631A0 (en) * | 2008-09-19 | 2011-04-30 | Paratek Pharmaceuticals Ind | Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment. |
| EP3061460A1 (en) | 2009-04-10 | 2016-08-31 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
| RU2647972C2 (ru) | 2010-05-12 | 2018-03-21 | Ремпекс Фармацеутикалс, Инк. | Тетрациклиновая композиция |
| CN101862293B (zh) * | 2010-06-22 | 2012-02-29 | 华南农业大学 | 盐酸多西环素的油混悬液及其制备方法和应用 |
| WO2012155146A1 (en) | 2011-05-12 | 2012-11-15 | Paratek Pharmaceuticals, Inc. | Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same |
| PT108978B (pt) | 2015-11-24 | 2020-03-09 | Hovione Farm S A | Sais de tetraciclinas |
| CN110087655A (zh) | 2016-11-01 | 2019-08-02 | 帕拉特克药品公司 | 9-氨基甲基米诺环素化合物及其在治疗社区获得性细菌性肺炎(cabp)中的用途 |
| WO2019016609A1 (en) | 2017-07-21 | 2019-01-24 | Allergan Pharmaceuticals International Limited | TREATMENT OF NON-INFLAMMATORY LESIONS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1430859A (OSRAM) * | 1960-05-23 | 1966-05-25 |
-
1968
- 1968-06-28 DE DE1767891A patent/DE1767891C3/de not_active Expired
- 1968-10-22 GB GB1228629D patent/GB1228629A/en not_active Expired
-
1969
- 1969-06-05 IL IL32350A patent/IL32350A/en unknown
- 1969-06-11 NL NL6908919A patent/NL6908919A/xx unknown
- 1969-06-18 BE BE734723D patent/BE734723A/xx not_active IP Right Cessation
- 1969-06-18 ES ES368496A patent/ES368496A1/es not_active Expired
- 1969-06-18 FI FI1809/69A patent/FI44395B/fi active
- 1969-06-18 NO NO2515/69A patent/NO130624C/no unknown
- 1969-06-18 CH CH933769A patent/CH522407A/fr not_active IP Right Cessation
- 1969-06-19 DK DK329869AA patent/DK127168B/da not_active IP Right Cessation
- 1969-06-19 SE SE6908788A patent/SE373036B/xx unknown
- 1969-06-19 IE IE845/69A patent/IE33167B1/xx unknown
- 1969-06-19 MX MX100333U patent/MX3351E/es unknown
- 1969-06-19 AT AT586269A patent/AT291441B/de not_active IP Right Cessation
- 1969-06-19 BR BR209929/69A patent/BR6909929D0/pt unknown
- 1969-06-19 FR FR696920595A patent/FR2011764B1/fr not_active Expired
- 1969-06-25 US US836591A patent/US3674859A/en not_active Expired - Lifetime
-
1973
- 1973-12-30 MY MY15/73A patent/MY7300015A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE734723A (OSRAM) | 1969-12-18 |
| US3674859A (en) | 1972-07-04 |
| DE1767891B2 (de) | 1980-02-21 |
| NO130624B (OSRAM) | 1974-10-07 |
| BR6909929D0 (pt) | 1973-02-08 |
| FR2011764A1 (OSRAM) | 1970-03-06 |
| MX3351E (es) | 1980-10-08 |
| AT291441B (de) | 1971-07-12 |
| SE373036B (OSRAM) | 1975-01-27 |
| IE33167L (en) | 1969-12-28 |
| IL32350A0 (en) | 1969-08-27 |
| IL32350A (en) | 1972-05-30 |
| DK127168B (da) | 1973-10-01 |
| GB1228629A (OSRAM) | 1971-04-15 |
| NO130624C (OSRAM) | 1975-01-15 |
| MY7300015A (en) | 1973-12-31 |
| FR2011764B1 (OSRAM) | 1973-07-13 |
| DE1767891A1 (de) | 1971-07-08 |
| IE33167B1 (en) | 1974-04-03 |
| CH522407A (fr) | 1972-06-30 |
| NL6908919A (OSRAM) | 1969-12-30 |
| ES368496A1 (es) | 1971-05-01 |
| FI44395B (OSRAM) | 1971-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1767891C3 (de) | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat | |
| DE1617576C3 (de) | Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-Komplexes | |
| DE2332878C2 (de) | Salze von Cephalosporinen mit Arginin und Lysin, ihre Herstellung und injizierbare pharmazeutische Zubereitungen | |
| DE2659152A1 (de) | Neue antibiotische praeparate zur pharmazeutischen verwendung | |
| DE2817335A1 (de) | Antibiotische tetracyclinhaltige mittel | |
| DE1417343A1 (de) | Verfahren zur Herstellung einer antibiotechnischen Zusammensetzung | |
| DE2323187A1 (de) | Verfahren zur herstellung einer stabilisierten, pulverfoermigen secretinzubereitung durch gefriertrocknung | |
| DE1802162A1 (de) | Neue N-Pyridylmethyliden-homocystein-thiolacton-Verbindung und Verfahren zu ihrer Herstellung | |
| CH647677A5 (de) | 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung. | |
| DE2501805A1 (de) | Arzneimittelzubereitungen und verfahren zu ihrer herstellung | |
| DE2754882A1 (de) | Pharmazeutische zusammensetzungen | |
| DE1965343A1 (de) | Arzneimittel,insbesondere zur Herabsetzung der Schleimviskositaet und Anwendung als hustenstillendes Mittel,und Verfahren zu seiner Herstellung | |
| DE1620177C3 (de) | N-(2-Hydroxyäthyl)-piperazinocarboxymethyl-tetracyclin, dessen pharmakologisch verwendbaren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1568519B1 (de) | Herstellung von Laurylsulfaten von Tetracyclinen | |
| DE2352910A1 (de) | Waessrige pharmazeutische zusammensetzung | |
| EP0152860B1 (de) | Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems | |
| DE1053734B (de) | Verfahren zur Loeslichmachung und Stabilisierung der Tetracyclinantibiotika | |
| DE899702C (de) | Verfahren zur Herstellung von Penicillinloesungen mit langdauernder Wirkung | |
| DE1670936C3 (de) | 3-Carbonsäureamido-chinoxalin-di-Nojdde-0,4), ein Verfahren zu ihrer Herstellung und diese enthaltende antibakterielle Mittel | |
| DE1593015C3 (de) | N.N'-Dimethyl-NJ'i'-di-detracyclinomethyl)-äthylendiamin und dessen Salze mit pharmakologisch unbedenklichen Mineral- und organischen Säuren sowie Verfahren zu deren Herstellung | |
| DE1019050B (de) | Verfahren zur Herstellung von konzentrierten waessrigen Loesungen von Salzen von Tetracyclinen | |
| AT274241B (de) | Verfahren zur Herstellung von Tetracyclin-Zubereitungen | |
| DE3701461C2 (OSRAM) | ||
| DE954726C (de) | Verfahren zur Herstellung von Komplexverbindungen des Calciums | |
| DE862341C (de) | Verfahren zur Herstellung von waessrigen Loesungen von Derivaten des p-Aminobenzolsulfonamids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |